Background The Rel/NF-κB transcription factors are often activated in solid or hematological malignancies. In most cases, NF-κB activation is found in malignant cells and results from activation of the canonical NF-κB pathway, leading to RelA and/or c-Rel activation. Recently, NF-κB activity in inflammatory cells infiltrating solid tumors has been shown to contribute to solid tumor initiation and progression. Noncanonical NF-κB activation, which leads to RelB activation, has also been reported in breast carcinoma, prostate cancer, and lymphoid leukemia. Methodology/Principal Findings Here we report a novel role for RelB in stromal cells that promote T-cell leukemogenesis. RelB deficiency delayed leukemia onset in the TEL-JAK2 transgenic mouse model of human T acute lymphoblastic leukemia. Bone marrow chimeric mouse experiments showed that RelB is not required in the hematopoietic compartment. In contrast, RelB plays a role in radio-resistant stromal cells to accelerate leukemia onset and increase disease severity. Conclusions/Significance The present results are the first to uncover a role for RelB in the crosstalk between non-hematopoietic stromal cells and leukemic cells. Thus, besides its previously reported role intrinsic to specific cancer cells, the noncanonical NF-κB pathway may also play a pro-oncogenic role in cancer microenvironmental cells.
References
[1]
Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18: 2195–2224.
[2]
Bassères DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25: 6817–6830.
[3]
Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441: 431–436.
[4]
Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, et al. (2006) Unravelling the complexities of the NF-kappaB signalling pathway using mouse knockout and transgenic models. Oncogene 25: 6781–6799.
[5]
Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, et al. (2007) A fourth IkappaB protein within the NF-kappaB signaling module. Cell 128: 369–381.
[6]
Derudder E, Dejardin E, Pritchard LL, Green DR, K？rner M, et al. (2003) RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem 278: 23278–23284.
[7]
Müller JR, Siebenlist U (2003) Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J Biol Chem 278: 12006–12012.
[8]
Yilmaz ZB, Weih DS, Sivakumar V, Weih F (2003) RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 22: 121–130.
[9]
Dejardin E (2006) The alternative NF-kappaB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem Pharmacol 72: 1161–1179.
[10]
Anderson G, Lane PJL, Jenkinson EJ (2007) Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol 7: 954–963.
[11]
Naquet P, Naspetti M, Boyd R (1999) Development, organization and function of the thymic medulla in normal, immunodeficient or autoimmune mice. Semin Immunol 11: 47–55.
[12]
Jost PJ, Ruland J (2007) Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109: 2700–2707.
[13]
Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C (2000) Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 14: 399–402.
[14]
Carrasco D, Rizzo CA, Dorfman K, Bravo R (1996) The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice. EMBO J 15: 3640–3650.
[15]
O'Neil J, Ventura JJ, Cusson N, Kelliher M (2003) NF-kappaB activation in premalignant mouse tal-1/scl thymocytes and tumors. Blood 102: 2593–2596.
[16]
Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, et al. (2007) Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 13: 70–77.
[17]
Xiao G, Rabson AB, Young W, Qing G, Qu Z (2006) Alternative pathways of NF-kappaB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 17: 281–293.
[18]
Zhang B, Wang Z, Li T, Tsitsikov EN, Ding H-F (2007) NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 110: 743–751.
[19]
Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, et al. (2007) Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12: 115–130.
[20]
Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, et al. (2007) Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12: 131–144.
[21]
Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, et al. (2000) TEL-JAK2 transgenic mice develop T-cell leukemia. Blood 95: 3891–3899.
[22]
Lacronique V, Boureux A, Della Valle V, Poirel H, Quang CT, et al. (1997) A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 278: 1309–1312.
[23]
Ryseck R-P, Bull P, Takamiya M, Bours V, Siebenlist U, et al. (1992) RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol 12: 674–684.
[24]
Sha WC, Liou H-C, Tuomanen EI, Baltimore D (1995) Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80: 321–330.
[25]
dos Santos NR, Rickman DS, de Reynies A, Cormier F, Williame M, et al. (2007) Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 109: 3972–3981.
[26]
Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, et al. (1995) Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373: 531–536.
[27]
Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, et al. (1995) Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell 80: 331–340.
[28]
Weih F, Durham SK, Barton DS, Sha WC, Baltimore D, et al. (1996) Both multiorgan inflammation and myeloid hyperplasia in RelB-deficient mice are T cell dependent. J Immunol 157: 3974–3979.
[29]
Lo D, Quill H, Burkly L, Scott B, Palmiter RD, et al. (1992) A recessive defect in lymphocyte or granulocyte function caused by an integrated transgene. Am J Pathol 141: 1237–1246.
[30]
DeKoning J, DiMolfetto L, Reilly C, Wei Q, Havran WL, et al. (1997) Thymic cortical epithelium is sufficient for the development of mature T cells in relB-deficient mice. J Immunol 158: 2558–2566.
[31]
Gray DHD, Seach N, Ueno T, Milton MK, Liston A, et al. (2006) Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells. Blood 108: 3777–3785.
[32]
Palmer DB, Viney JL, Ritter MA, Hayday AC, Owen MJ (1993) Expression of the alpha beta T-cell receptor is necessary for the generation of the thymic medulla. Dev Immunol 3: 175–179.
[33]
Weih F, Caamano J (2003) Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev 195: 91–105.
[34]
Bellavia D, Campese AF, Alesse E, Vacca A, Felli MP, et al. (2000) Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice. EMBO J 19: 3337–3348.
[35]
Heino M, Peterson P, Sillanp？？ N, Guérin S, Wu L, et al. (2000) RNA and protein expression of the murine autoimmune regulator gene (Aire) in normal, RelB-deficient and in NOD mouse. Eur J Immunol 30: 1884–1893.
[36]
Wu L, D'Amico A, Winkel KD, Suter M, Lo D, et al. (1998) RelB is essential for the development of myeloid-related CD8alpha- dendritic cells but not of lymphoid-related CD8alpha+ dendritic cells. Immunity 9: 839–847.
[37]
Anderson G, Jenkinson WE, Jones T, Parnell SM, Kinsella FAM, et al. (2006) Establishment and functioning of intrathymic microenvironments. Immunol Rev 209: 10–27.
[38]
Petrie HT, Zú？iga-Pflücker JC (2007) Zoned out: functional mapping of stromal signaling microenvironments in the thymus. Annu Rev Immunol 25: 649–679.
[39]
Derbinski J, Kyewski B (2005) Linking signalling pathways, thymic stroma integrity and autoimmunity. Trends Immunol 26: 503–506.
[40]
Lo JC, Chin RK, Lee Y, Kang H-S, Wang Y, et al. (2003) Differential regulation of CCL21 in lymphoid/nonlymphoid tissues for effectively attracting T cells to peripheral tissues. J Clin Invest 112: 1495–1505.
[41]
Zhu M, Chin RK, Tumanov AV, Liu X, Fu Y-X (2007) Lymphotoxin receptor is required for the migration and selection of autoreactive T cells in thymic medulla. J Immunol 179: 8069–8075.
[42]
Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, et al. (2004) Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J 23: 4202–4210.
[43]
Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, et al. (2002) The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 17: 525–535.
[44]
Cupedo T, Mebius RE (2005) Cellular interactions in lymph node development. J Immunol 174: 21–25.
[45]
Gray DHD, Ueno T, Chidgey AP, Malin M, Goldberg GL, et al. (2005) Controlling the thymic microenvironment. Curr Opin Immunol 17: 137–143.
[46]
Hare KJ, Jenkinson EJ, Anderson G (2000) An essential role for the IL-7 receptor during intrathymic expansion of the positively selected neonatal T cell repertoire. J Immunol 165: 2410–2414.
[47]
Hare KJ, Wilkinson RW, Jenkinson EJ, Anderson G (1998) Identification of a developmentally regulated phase of postselection expansion driven by thymic epithelium. J Immunol 160: 3666–3672.
[48]
Barata JT, Cardoso AA, Boussiotis VA (2005) Interleukin-7 in T-cell acute lymphoblastic leukemia: an extrinsic factor supporting leukemogenesis? Leuk Lymphoma 46: 483–495.
[49]
Scupoli MT, Perbellini O, Krampera M, Vinante F, Cioffi F, et al. (2007) Interleukin 7 requirement for survival of T-cell acute lymphoblastic leukemia and human thymocytes on bone marrow stroma. Haematologica 92: 264–266.
[50]
Scupoli MT, Vinante F, Krampera M, Vincenzi C, Nadali G, et al. (2003) Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7. Haematologica 88: 1229–1237.
[51]
Winter SS, Sweatman JJ, Lawrence MB, Rhoades TH, Hart AL, et al. (2001) Enhanced T-lineage acute lymphoblastic leukaemia cell survival on bone marrow stroma requires involvement of LFA-1 and ICAM-1. Br J Haematol 115: 862–871.
[52]
Dumortier A, Jeannet R, Kirstetter P, Kleinmann E, Sellars M, et al. (2006) Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol 26: 209–220.
[53]
Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, et al. (2005) RelB/p52 NF-kappaB complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor IkappaB-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 25: 10136–10147.
[54]
Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, et al. (2006) RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 25: 1554–1559.
[55]
Clapcote SJ, Roder JC (2005) Simplex PCR assay for sex determination in mice. Biotechniques 38: 702.704706
[56]
Olnes MI, Kurl RN (1994) Isolation of nuclear extracts from fragile cells: a simplified procedure applied to thymocytes. Biotechniques 17: 828–829.
[57]
Bosselut R, Duvall JF, Gégonne A, Bailly M, Hémar A, et al. (1990) The product of the c-ets-1 proto-oncogene and the related Ets2 protein act as transcriptional activators of the long terminal repeat of human T cell leukemia virus HTLV-1. EMBO J 9: 3137–3144.
[58]
Sen R, Baltimore D (1986) Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 46: 705–716.
[59]
Ballard DW, Walker WH, Doerre S, Sista P, Molitor JA, et al. (1990) The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell 63: 803–814.
